Elixinol Global Ltd
Elixinol Wellness Limited, a holding company, provides healthy products in Australia, the Americas, and internationally. The company provides human nutrition, human wellness, pet wellness, and superfood ingredients under Hemp Foods Australia, Mt Elephant, The Healthy Chef, Soul Foods, Ananda Equine, and Field Day brands. It distributed through grocery, wholesale, and e-commerce channels for white… Read more
Elixinol Global Ltd (ELLXF) - Total Assets
Latest total assets as of June 2025: $16.58 Million USD
Based on the latest financial reports, Elixinol Global Ltd (ELLXF) holds total assets worth $16.58 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Elixinol Global Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Elixinol Global Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Elixinol Global Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Elixinol Global Ltd's total assets of $16.58 Million consist of 38.9% current assets and 61.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.8% |
| Accounts Receivable | $1.61 Million | 8.7% |
| Inventory | $3.89 Million | 21.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.81 Million | 26.1% |
| Goodwill | $1.37 Million | 7.4% |
Asset Composition Trend (2016–2024)
This chart illustrates how Elixinol Global Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Elixinol Global Ltd's current assets represent 38.9% of total assets in 2024, an increase from 22.1% in 2016.
- Cash Position: Cash and equivalents constituted 5.8% of total assets in 2024, down from 18.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, a decrease from 75.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 26.1% of total assets.
Elixinol Global Ltd Competitors by Total Assets
Key competitors of Elixinol Global Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Elixinol Global Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Elixinol Global Ltd generates 0.81x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Elixinol Global Ltd is currently not profitable relative to its asset base.
Elixinol Global Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.92 | 1.81 | 4.52 |
| Quick Ratio | 0.47 | 0.92 | 3.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-551.00K | $ 3.69 Million | $ 22.57 Million |
Elixinol Global Ltd - Advanced Valuation Insights
This section examines the relationship between Elixinol Global Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.68 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 57.5% |
| Total Assets | $18.45 Million |
| Market Capitalization | $1.24 Million USD |
Valuation Analysis
Below Book Valuation: The market values Elixinol Global Ltd's assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Elixinol Global Ltd's assets grew by 57.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Elixinol Global Ltd (2016–2024)
The table below shows the annual total assets of Elixinol Global Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $18.45 Million | +57.54% |
| 2023-12-31 | $11.71 Million | -13.16% |
| 2022-12-31 | $13.48 Million | -46.77% |
| 2021-12-31 | $25.33 Million | -40.35% |
| 2020-12-31 | $42.47 Million | -64.92% |
| 2019-12-31 | $121.07 Million | -21.23% |
| 2018-12-31 | $153.69 Million | +46.37% |
| 2017-12-31 | $105.00 Million | +1.15% |
| 2016-12-31 | $103.81 Million | -- |